Marina Basina News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marina basina. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marina Basina Today - Breaking & Trending Today

Investegate |Renalytix PLC Announcements | Renalytix PLC: New data for KidneyIntelX


and Corresponding Risk Reduction Over Time
 
 
NEW YORK, June 28, 2021 -
Renalytix plc
(LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating
KidneyIntelX™
can be effective at monitoring therapeutic response and  improvements in kidney health over time in adults with type 2 diabetes.  By accurately assessing therapeutic response, particularly in patients at high risk for kidney failure, KidneyIntelX can potentially address a major barrier for primary care physicians and specialists in using new pharmaceuticals to slow kidney disease and improve outcomes. The data from an international study of 1,100 individuals with diabetic kidney disease (DKD) in the CANagliflozin Cardiovascular Assessment Study (CANVAS), was presented at the American Diabetes Association 81st Scientific Sessions Virtual Meeting (June 25-29, 2021). ....

United States , Paul Mcmanus Lianne Cawthorne , Marina Basina , James Mccullough , Nicholas Moore , Michaelj Donovan , Alex Price , Daniel Adams , Gary Clarence , Janssen Research , Centers For Disease , Wake Forest Baptist Health , Drug Administration , University Of Utah , American Diabetes Association , Atrium Health , Investec Bank , Exchange Commission , Mount Sinai Health System , World Congress , Therapy Response , Corresponding Risk Reduction Over , Cardiovascular Assessment Study , Scientific Sessions Virtual Meeting , Clinical Professor , Stanford University School ,

Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure


Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure
Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes
April 05, 2021 07:00 ET
| Source:
Renalytix AI plc.
Renalytix AI plc.
New York, New York, UNITED STATES
NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care. The results of the study, which is the second peer-reviewed clinical validation study on KidneyIntelX, have been p ....

United States , Michaelj Donovan , Paul Mcmanus Lianne Cawthorne , Marina Basina , Jennifer Moritz , Centers For Disease , European Association For The Study Of Diabetes , Drug Administration , Exchange Commission , Joslin Diabetes Center , Mount Sinai Health System , Stanford Health Care , European Association , Mount Sinai Health , Clinical Professor , Stanford Medicine , Medical Director , Inpatient Diabetes , Stanford Health , United States Medicare , Chief Medical Officer , Kidney Disease , Disease Control , Breakthrough Designation , Private Securities Litigation Reform Act , Nasdaq Rnlx ,